Valdeolivas-Casillas N, Polo-Rodríguez I, Medina-Montalvo MS, Vélez MD, Cabrera-Hernández A, García-Rodríguez MM

Language: Spanish
References: 15
Page: 41-44
PDF size: 381.29 Kb.

ABSTRACT

We report a 64-year-old male with a spindle cell cutaneous carcinoma. A month and a half after the diagnosis, the patient presented metastatic spread, and he died few months later. This histological type and the aggressive course give this case special interest.

REFERENCES

1. Martorell-Calatayud A, Sanmartín-Jiménez O, Cruz-Mojarrieta J, Guillén-Barona C. Carcinoma epidermoide cutáneo: definiendo la variante de alto riesgo. Actas Dermosifiliogr. 2013; 104: 367-379.

2. Nuño-González A, Vicente-Martín FJ, Pinedo-Moraleda F, López-Estebaranz JL. Carcinoma epidermoide cutáneo de alto riesgo. Actas Dermosifiliogr. 2012; 103: 567-578.

3. Farasat S, Yu SS, Neel VA, Nehal KS, Lardaro T, Mihm MC et al. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol. 2011; 64: 1051-1059.

4. Cassarino DS, DeRienzo DP, Barr RJ. Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification. J Cutan Pathol. 2006; 33: 191-206.

5. Morgan MB, Purohit C, Anglin TR. Immunohistochemical distinction of cutaneous spindle cell carcinoma. Am J Dermatopathol. 2008; 30: 228-232.

6. Evans HL, Smith JL. Spindle cell squamous carcinomas and sarcoma-like tumors of the skin. A comparative study of 38 cases. Cancer. 1980; 45: 2687-2697.

7. Shimokawa M, Haraguchi M, Kobayashi W, Higashi Y, Matsuschita S, Kawai K el al. The transcription factor snail expressed in cutaneous squamous cell carcinoma induces epithelial-mesenchymal transition and down-regulates COX-2. Biochemical Biophysical Res Communications. 2013; 430: 1078-1082.

8. Kanner WA, Brill LB, Patterson JW, Wick MR. CD10, p63 and CD99 expression in the differential diagnosis of atypical fibroxanthoma, spindle cell squamous cell carcinoma and desmoplastic melanoma. J Cutan Pathol. 2010; 37: 744-750.

9. Wieland CN, Rayna D, Weenig RH, Comfere NI. The role of CD10 in distinguishing atypical fibroxanthoma from sarcomatoid (spindle cell) squamous cell carcinoma. J Cutan Pathol. 2011; 38: 884-888.

10. Sigel JE, Skacel M, Bergfeld WF, House NS, Rabkin MS, Goldblum JR. The utility of cytokeratin 5/6 in the recognition of cutaneous spindle cell squamous cell carcinoma. J Cutan Pathol. 2001; 28: 520-524.

11. Shin DM, Glisson BS, Khurri FR, Clifford JL, Clayman G, Benner SE et al. Phase II and biologic study of interferon alfa, retinoic acid and cisplatin in advanced squamous skin cancer. J Clin Oncol. 2002; 20: 364-370.

12. Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011; 29: 3419-3426.

13. Bryan KO, Sherman W, Niedt GW, Taback B, Manolidis S, Wang A et al. An evolving paradigm for the workup and management of high-risk cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2013; 69: 594-602.

14. Ross AS, Schmults CD. Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature. Dermatol Surg. 2006; 32: 1309-1321.

15. Matsumura T, Kumakiri M, Sato-Matsumura KC, Koizumi H, Ohkaeara A, Tanifuji J et al. An aggressive spindle cell squamous carcinoma arising in a patient with long-standing erythroderma. J Dermatol. 1994; 21: 746-750.